Home  »  Finance   »  New Big Money Means Core Laboratories N.V. (CLB) I...

New Big Money Means Core Laboratories N.V. (CLB) Investors Could Reap Benefit

Core Laboratories N.V. (NYSE: CLB) is -5.92% lower on its value in year-to-date trading and has touched a low of $13.19 and a high of $35.83 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CLB stock was last observed hovering at around $21.12 in the last trading session, with the day’s loss setting it -0.13% off its average median price target of $20.00 for the next 12 months. It is also 34.41% off the consensus price target high of $32.00 offered by 11 analysts, but current levels are -61.46% lower than the price target low of $13.00 for the same period.

Currently trading at $20.99, the stock is 0.50% and 15.82% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.24 million and changing -0.62% at the moment leaves the stock -6.92% off its SMA200. CLB registered -18.67% loss for a year compared to 6-month loss of -19.73%.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


The stock witnessed a 4.95% gain in the last 1 month and extending the period to 3 months gives it a 18.59%, and is -5.87% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.57% over the week and 5.37% over the month.

Core Laboratories N.V. (CLB) has around 3700 employees, a market worth around $1.01B and $487.30M in sales. Current P/E ratio is 64.19 and Fwd P/E is 21.44. Profit margin for the company is 3.20%. Distance from 52-week low is 59.14% and -41.42% from its 52-week high. The company has generated returns on investments over the last 12 months (8.50%).

Core Laboratories N.V. (CLB) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Core Laboratories N.V. (CLB) is a “Hold”. 11 analysts offering their recommendations for the stock have an average rating of 3.00, where 5 rate it as a Hold and 2 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.

Core Laboratories N.V. is expected to release its quarterly report on 02/01/2023.The EPS is expected to grow by 119.30% this year

Core Laboratories N.V. (CLB) Top Institutional Holders

The shares outstanding are 46.34M, and float is at 46.13M with Short Float at 8.77%.

Core Laboratories N.V. (CLB) Insider Activity

A total of 8 insider transactions have happened at Core Laboratories N.V. (CLB) in the last six months, with sales accounting for 4 and purchases happening 4 times.

Core Laboratories N.V. (CLB): Who are the competitors?

The company’s main competitors (and peers) include Schlumberger Limited (SLB) that is trading 64.91% up over the past 12 months and Helix Energy Solutions Group Inc. (HLX) that is 80.75% higher over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.